SULT2B1B sulfotransferase: Induction by vitamin D receptor and reduced expression in prostate cancer

Medicine and Dentistry

• Prostate Cancer 100%
• Tissues 100%
• Prasterone 80%
• Vitamin D Receptor 60%
• Neoplasm 40%
• Specimen 40%
• Cancer Cell 40%
• Immunohistochemistry 40%
• Promoter Region 40%
• Sulfotransferase 40%
• Messenger RNA 20%
• Protein 20%
• Ligand 20%
• In Vitro 20%
• Stimulation 20%
• Malignant Neoplasm 20%
• Prostatectomy 20%
• Metabolism 20%
• Combination Therapy 20%
• Element 20%
• Disease Exacerbation 20%
• Cancer Growth 20%
• Cholesterol 20%
• Precursor 20%
• Formaldehyde 20%
• Androgen Receptor 20%
• Polyclonal Antibody 20%
• Steroid 20%
• Androstanolone 20%
• Androstenedione 20%
• Calcitriol 20%
• Cancer Tissue 20%
• Steroidogenic Enzymes 20%
• Retinoid X Receptor 20%
• 3(or 17)beta Hydroxysteroid Dehydrogenase 20%
• Oxysterol 20%
• Aldo Keto Reductase 20%
• Steroid 5alpha Reductase 1 20%
• Androgen Synthesis 20%
• Hydroxysteroid 20%
• Cells 20%
• Therapeutic Procedure 20%
• Prostate 20%
• Patient 20%
• Gland 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Prasterone 80%
• Vitamin D Receptor 60%
• Neoplasm 40%
• Western Blot 40%
• Sulfotransferase 40%
• Protein 20%
• Messenger RNA 20%
• Ligand 20%
• Leporidae 20%
• DNA 20%
• Disease Exacerbation 20%
• Androgen 20%
• Polyclonal Antibody 20%
• Element 20%
• Cholesterol 20%
• Steroids 20%
• Androstanolone 20%
• Calcitriol 20%
• Cancer Growth 20%
• Malignant Neoplasm 20%
• Retinoid X Receptor 20%
• Mouse 20%
• 3(or 17)beta Hydroxysteroid Dehydrogenase 20%
• Androgen Receptor 20%
• Formaldehyde 20%
• Androstenedione 20%
• Aldo Keto Reductase 20%
• Hydroxysteroid 20%
• Protein Hydrolysate 20%
• Oxysterol 20%